Edwards Lifesciences (EW) has provided an announcement.
Edwards Lifesciences Corporation has successfully completed the sale of its Critical Care product group to Becton, Dickinson and Company. Following the sale, the company’s Board of Directors has approved an additional $1.5 billion for share repurchases, alongside entering into a $500 million accelerated share repurchase agreement. This move signifies a strategic shift and a potential return of value to shareholders.
Learn more about EW stock on TipRanks’ Stock Analysis page.
